C4 Therapeutics is the newest member of the R&D Logic Customer Community!
March 2024
C4 Therapeutics is dedicated to delivering on the promise of targeted protein degradation (TPD) to create a new generation of medicines that transforms patients’ lives.
Karuna Therapeutics Selects R&D Time!
January 2024
Karuna is a biopharmaceutical company driven to discover, develop and deliver transformative medicines for people living with psychiatric and neurological conditions.
Protego Biopharm Joins R&D Logic!
August 2023
Protego Biopharma focuses on the discovery and development of first- or best-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various systemic amyloid diseases, such as light chain (LC) amyloidosis.
Sonoma Biotherapeutics Selects R&D Time
August 2023
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.
Sosei Heptares Joins our Customer Community!
September 2022
With offices in Cambridge and London, UK, Sosei Heptares is focused on the discovery and early development of new medicines originating from their proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities.
CRISPR Therapeutics is the latest life science company to select R&D Logic!
May 2022
With offices in Cambridge, MA, San Francisco, CA and Zug Switzerland CRISPR Therapeutics is focused on developing transformative gene-based medicines for serious human diseases.
R&D Logic is proud to welcome Disc Medicine!
April 2022
Located in Watertown, MA, Disc Medicines is committed to building a brighter future for patients. Using new discoveries and insights in hematology, they are advancing the frontiers of biology to create life-changing medicines.
Ensoma Joins the R&D Logic Community!
March 2022
Located in Boston, MA, Ensoma is expanding the boundaries of genetic medicine – from rare monogenic illnesses to prevalent polygenic conditions such as autoimmune disease and cancer that affect millions around the world.
Foresite Labs Selects R&D Logic!
June 2021
Based in San Francisco and Boston, Foresite Labs partners broadly to launch life sciences and healthcare companies that use the tools of data science to solve our greatest unmet medical needs.
Spark Therapeutics joins the R&D Logic Customer Community!
May 2021
Headquartered in Philadelphia, PA Spark Therapeutics, is committed to discovering, developing and delivering gene therapies to address genetic diseases including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.
KSQ Therapeutics is the latest life science company to select R&D Time!
March 2021
Headquartered in Cambridge, MA, KSQ is a preclinical-stage biotech that has rapidly advanced the field of CRISPR-enabled functional genomics, from in vitro cell autonomous screens to more complex genome-scale screens of immune cells in vivo.
R&D Logic is proud to announce Arcus Biosciences has joined the R&D Logic customer community!
February 2021
Headquartered in Hayward, CA, Arcus was founded with the vision of bringing together scientists, physicians, advisors, and other leaders with significant content-matter expertise to focus on developing highly-combinable, best-in-class cancer therapies.
Seres Therapeutics chooses R&D Logic’s life sciences focused project time collection solution, R&D Time.
November 2020 – Headquartered in Cambridge, MA Seres Therapeutics is a late-clinical stage biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.
Atreca acknowledges R&D Logic's life sciences expertise by selecting R&D Time for Project Time Collection.
October 2020 — Headquartered in South San Francisco, CA, Atreca focuses on the immune response of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies, including those in our lead programs in Oncology.
Adagio recognizes R&D Logic's life science expertise by adding R&D Logic to their financial system suite.
October 2020 — With offices in Waltham, MA, Adagio's mission is to provide an effective long-term solution for the global Coronavirus challenge.
Molecular Templates has selected R&D Logic's R&D Time software!
September 2020 — Located in Austin, TX, Molecular Templates is focused on the discovery, development and commercialization of next generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancer.
Celsius Therapeutics joins other leading Biotech companies by choosing R&D Time for Project Time Collection and FTE reporting.
August 2020 — With offices in Cambridge, MA, Celsius' mission is to develop life-saving medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.
Beam Therapeutics is now a member of the R&D Logic Customer Community - welcome Beam!
February 2020 — With offices in Cambridge, MA, Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
ShouTi Pharma, R&D Logic's newest customer, is using R&D Time for international project time collection.
January 2020 — With US offices in San Diego and South San Francisco, Shouti Pharmaceuticals will be using R&D Logic's R&D Time to manage and prioritize portfolio resources.
Turnstone Biologics chooses R&D Time for Project Time Collection and FTE reporting.
December 2019 — With offices in Ottawa and New York City, Turnstone Biologics' mission is to deliver breakthrough viral immunotherapies to improve survival for patients with cancer.